v3.26.1
SEGMENT REPORTING (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Segment Reporting [Line Items]        
Number of reportable segments | segment     1  
Number of segments | segment     1  
Revenues        
Total revenues $ 120,877 $ 97,662 $ 215,350 $ 171,776
Less        
Cost of sales 5,759 12,403 10,570 24,706
Stock-based compensation 15,316 11,687 29,474 23,775
Loss before provision for income taxes (16,611) (19,078) (54,208) (59,363)
Net loss (16,721) (19,079) (54,326) (60,223)
AstraZeneca | AZ Termination Agreement        
Less        
Cost of sales   3,800   12,700
Maximum potential payment per agreement   75,000   75,000
Reportable Segment        
Revenues        
Total revenues 120,877 97,662 215,350 171,776
Less        
Research and development 23,195 13,251 40,781 24,586
Selling 66,949 57,952 134,344 114,752
General and administrative 22,083 16,764 45,399 34,701
Stock-based compensation 15,316 11,687 29,474 23,775
Loss before provision for income taxes (12,425) (14,395) (45,218) (50,744)
Other reconciliation items (4,296) (4,684) (9,108) (9,479)
Net loss (16,721) (19,079) (54,326) (60,223)
Product sales, net        
Revenues        
Total revenues 118,129 90,077 211,502 157,891
Product sales, net | Reportable Segment        
Revenues        
Total revenues 118,129 90,077 211,502 157,891
Less        
Cost of sales 3,689 3,245 6,564 5,585
Other cost of revenue | Reportable Segment        
Revenues        
Total revenues 2,748 7,585 3,848 13,885
Less        
Cost of sales $ 2,070 $ 9,158 $ 4,006 $ 19,121